Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.37 |
| ▸ | KDM5A | P29375 | 2/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18195632 | 0.82 | KDM5A (0.40) | DNM1KDM5AKDM4CMEN1KMT2A | |
| SCHEMBL19822045 | 0.82 | DNM1 (0.42) | DNM1KDM5AKDM4C | |
| SCHEMBL25634868 | 0.77 | KDM5A (0.46) | DNM1KDM5AKDM4CMEN1KMT2A | |
| SCHEMBL10081251 | 0.76 | DNM1 (0.42) | DNM1KDM5AKDM4CMEN1KMT2A | |
| SCHEMBL17448448 | 0.72 | MEN1 (0.57) | DNM1KDM5AKDM4CMEN1KMT2A | |
| SCHEMBL23072804 | 0.71 | DNM1 (0.42) | DNM1 | |
| SCHEMBL22692993 | 0.71 | CYP1A2 (0.53) | DNM1KDM5AKDM4CMEN1KMT2A | |
| SCHEMBL2607007 | 0.71 | MEN1 (0.45) | DNM1KDM5AKDM4CMEN1KMT2A | |
| SCHEMBL20674797 | 0.71 | DNM1 (0.44) | DNM1KDM5AKDM4C | |
| SCHEMBL19822022 | 0.71 | DNM1 (0.37) | DNM1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10342761-B2 | Method of encapsulating a nucleic acid in a lipid nanoparticle host | NOVARTIS AG (CH) | 2019-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10342761-B2 | Method of encapsulating a nucleic acid in a lipid nanoparticle host | POLN, POLRMT, RNGTT | DNM1 970/4885KDM5A 4854/4885KDM4C 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.